Background: Chronic inflammation is increasingly recognized as a crucial contributor to sarcopenia pathogenesis, but accurate diagnosis remains a challenge.

Aim: Our study aims to investigate the relationship between sarcopenia and the Systemic Immune-Inflammation Index (SII), a comprehensive indicator of inflammation.

Methods: This cross-sectional study enrolled 632 patients. All participants underwent a comprehensive geriatric assessment. Sarcopenia was assessed through the evaluation of handgrip strength and calf circumference. To determine the SII, we used the formula: Platelet count (10/mm)×Neutrophil count (10/mm) / Lymphocyte count (10/mm).

Results: The average age of the participants was 74.8 ± 6.4, and 62.3% (n = 394) were female. Patients were grouped as non-sarcopenic and sarcopenic. The non-sarcopenic group had 536 patients (84.8%), while the sarcopenic group comprised 96 patients (15.2%). Sarcopenic patients showed a higher median SII score than the non-sarcopenic group (p < 0.001). Multivariate logistic regression analysis revealed that the SII score was significantly and independently associated with sarcopenia even after adjusting for potential confounding factors (β = 1.002, 95% CI = 1.001-1.003, p < 0.001). The ROC analysis identified the optimal cut-off for SII in predicting sarcopenia as > 765. At this threshold, the negative predictive values were determined to be 88.1%, with a specificity of 88%.

Conclusion: SII is significantly associated with sarcopenia in a geriatric outpatient population, and a population-specific SII cut-off may serve as a novel, simple, and practical biomarker for diagnosing sarcopenia.

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12877-025-05686-2DOI Listing

Publication Analysis

Top Keywords

systemic immune-inflammation
8
cross-sectional study
8
non-sarcopenic group
8
patients
5
association systemic
4
sarcopenia
4
immune-inflammation sarcopenia
4
sarcopenia older
4
older adults
4
adults cross-sectional
4

Similar Publications

The prognostic value of systemic immune-inflammation index in patients with unresectable hepatocellular carcinoma treated with immune-based therapy.

Biomark Res

January 2025

Department of Liver Surgery and Transplantation, Liver Cancer Institute and Zhongshan Hospital, Fudan University180 Fenglin Road, Shanghai, 200032, China.

Background: Predicting the efficacy of immune-based therapy in patients with unresectable hepatocellular carcinoma (HCC) remains a clinical challenge. This study aims to evaluate the prognostic value of the systemic immune-inflammation index (SII) in forecasting treatment response and survival outcomes for HCC patients undergoing immune-based therapy.

Methods: We analyzed a cohort of 268 HCC patients treated with immune-based therapy from January 2019 to March 2023.

View Article and Find Full Text PDF

Background: In recent years, the association between systemic immune-inflammation index (SII) and the prognosis of patients with colorectal cancer (CRC) has remained a topic of considerable debate. To address this, the present study was carried out to investigate the prognostic significance of SII in CRC.

Methods: Databases including PubMed, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL), and Web of Science were scrutinized up to March 27, 2024.

View Article and Find Full Text PDF

Background: Chronic inflammation is increasingly recognized as a crucial contributor to sarcopenia pathogenesis, but accurate diagnosis remains a challenge.

Aim: Our study aims to investigate the relationship between sarcopenia and the Systemic Immune-Inflammation Index (SII), a comprehensive indicator of inflammation.

Methods: This cross-sectional study enrolled 632 patients.

View Article and Find Full Text PDF

IL-17 and IL-23 inhibitors have shown successful results in improving skin lesions in the treatment of moderate-to-severe plaque psoriasis. However, psoriasis is a chronic inflammatory disease characterized by systemic inflammation including joints in addition to skin lesions. Therefore, in this retrospective and observational cohort study, we aimed to evaluate the effect of IL-17 inhibitors (secukinumab and ixekizumab) and IL-23 inhibitors (risankizumab and guselkumab) on systemic inflammation in psoriasis.

View Article and Find Full Text PDF

Background: Systemic immune-inflammation index (SII) and neutrophil-to-lymphocyte ratio (NLR) are novel inflammatory markers based on neutrophil, platelet and lymphocyte counts. Atherosclerosis is a chronic inflammatory vascular disease. This study aimed to verify the predictive value of the clinical parameters such as systemic immune-inflammation index (SII) and neutrophil-to-lymphocyte ratio (NLR) for the severity in Large Artery Atherosclerosis (LAA) stroke patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!